Ticker brief
CTMX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
5
crowd 14d
+0.6σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-19 → 2026-08-27 · now +0.42 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 2 | +0.50 |
| @PersimmonTI | A | -0.57 | 1 | +0.10 |
| @BioStocks | C | -3.02 | 1 | +0.50 |
| @OzmosiHealth | C | · | 1 | +0.40 |
| @BiopharmIQ | B | · | 1 | +0.20 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @BiopharmIQ | +0.20 | Biotech mover list links price changes to company-specific catalysts. | · | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.40 | FDA granted Fast Track designation to Varseta-M for metastatic colorectal cancer. | · | tweet ↗ |
| 2026-08-27 | @semodough | +0.50 | Reports Fast Track designation and outlines a planned registrational study plus a year-end data package. | · | tweet ↗ |
| 2026-08-27 | @semodough | +0.50 | CytomX announced FDA Fast Track designation for Varseta-M in relapsed or refractory metastatic colorectal cancer. | · | tweet ↗ |
| 2026-08-27 | @BioStocks | +0.50 | Reports FDA Fast Track designation for varsetatug masetecan in metastatic colorectal cancer. | · | tweet ↗ |
| 2026-08-19 | @PersimmonTI | +0.10 | Notes unusual premarket volume, with the linked chart needed for details. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.